Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Altered Expression Pattern of Clock Genes in a Rat Model of Depression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Depression and BMI influences the serum vascular endothelial growth factor level

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Relationship of frontal D2/3 binding potentials to cognition: a study of antipsychotic-naive schizophrenia patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Henrik Nørbak-Emig
  • Bjørn H Ebdrup
  • Birgitte Fagerlund
  • Claus Svarer
  • Hans Rasmussen
  • Lars Friberg
  • Peter N Allerup
  • Egill Rostrup
  • Lars H Pinborg
  • Birte Y Glenthøj
Vis graf over relationer

BACKGROUND: We have previously reported associations between frontal D2/3 receptor binding potential positive symptoms and cognitive deficits in antipsychotic-naïve schizophrenia patients. Here, we examined the effect of dopamine D2/3 receptor blockade on cognition. Additionally, we explored the relation between frontal D2/3 receptor availability and treatment effect on positive symptoms.

METHODS: Twenty-five antipsychotic-naïve first-episode schizophrenia patients were examined with the Positive and Negative Syndrome Scale, tested with the cognitive test battery Cambridge Neuropsychological Test Automated Battery, scanned with single-photon emission computerized tomography using the dopamine D2/3 receptor ligand [(123)I]epidepride, and scanned with MRI. After 3 months of treatment with either risperidone (n=13) or zuclopenthixol (n=9), 22 patients were reexamined.

RESULTS: Blockade of extrastriatal dopamine D2/3 receptors was correlated with decreased attentional focus (r = -0.615, P=.003) and planning time (r = -0.436, P=.048). Moreover, baseline frontal dopamine D2/3 binding potential and positive symptom reduction correlated positively (D2/3 receptor binding potential left frontal cortex rho = 0.56, P=.003; D2/3 receptor binding potential right frontal cortex rho = 0.48, P=.016).

CONCLUSIONS: Our data support the hypothesis of a negative influence of D2/3 receptor blockade on specific cognitive functions in schizophrenia. This is highly clinically relevant given the well-established association between severity of cognitive disturbances and a poor functional outcome in schizophrenia. Additionally, the findings support associations between frontal D2/3 receptor binding potential at baseline and the effect of antipsychotic treatment on positive symptoms.

OriginalsprogEngelsk
TidsskriftThe international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)
Vol/bind19
Udgave nummer5
Sider (fra-til)006
ISSN1461-1457
DOI
StatusUdgivet - maj 2016

ID: 46462180